{
    "clinical_study": {
        "@rank": "151326", 
        "arm_group": [
            {
                "arm_group_label": "Testosterone replacement", 
                "arm_group_type": "Experimental", 
                "description": "Testosterone replacement for hypogonadism."
            }, 
            {
                "arm_group_label": "Waitlist control", 
                "arm_group_type": "Other", 
                "description": "This arm involves watchful waiting."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to develop an effective treatment intervention for chronic pain,\n      symptomatic hypogonadism, and opioid addiction"
        }, 
        "brief_title": "Testosterone Replacement for Male Opioid Agonist Maintained Patients", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Pain", 
            "Opioid Addiction", 
            "Symptomatic Hypogonadism"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypogonadism", 
                "Behavior, Addictive"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study aims to assess the initial efficacy of testosterone replacement in male opioid\n      agonist patients with symptomatic hypogonadism and chronic pain.\n\n      The study has two specific aims:\n\n        1. To estimate, in male opioid agonist maintained patients, the prevalence of\n           (a)symptomatic hypogonadism and (b) co-occurring symptomatic hypogonadism and chronic\n           pain.\n\n        2. To conduct a pilot randomized clinical trial to obtain data regarding the feasibility,\n           acceptability, and efficacy (compared to waitlist control) of testosterone replacement\n           for male patients with POD and symptomatic hypogonadism treated with opioid agonist\n           maintenance treatment (N=40)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Between 18 and 50 years of age\n\n          -  Male buprenorphine- or methadone-maintained patients at the APT Foundation\n\n          -  Moderate to severe chronic pain\n\n          -  Meet criteria for symptomatic hypogonadism\n\n          -  Understand English\n\n          -  Interested in receiving testosterone replacement\n\n        Exclusion Criteria:\n\n          -  Current suicide or homicide risk\n\n          -  Life-threatening or unstable medical condition\n\n          -  Known or suspected prostate or chest cancer or history of polycythemia"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01873989", 
            "org_study_id": "1105008492"
        }, 
        "intervention": [
            {
                "arm_group_label": "Testosterone replacement", 
                "intervention_name": "Testosterone replacement", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Waitlist control", 
                "intervention_name": "Waitlist control", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Testosterone", 
                "Testosterone enanthate", 
                "Testosterone undecanoate", 
                "Testosterone 17 beta-cypionate", 
                "Methyltestosterone", 
                "Analgesics, Opioid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Chronic pain", 
            "Opioid addiction", 
            "Symptomatic hypogonadism", 
            "Testosterone replacement", 
            "Opioid agonist maintenance", 
            "Methadone", 
            "Buprenorphine"
        ], 
        "lastchanged_date": "January 13, 2014", 
        "location": {
            "contact": {
                "email": "christopher.cutter@yale.edu", 
                "last_name": "Christopher J Cutter, Ph.D.", 
                "phone": "203-285-2717"
            }, 
            "contact_backup": {
                "email": "declan.barry@yale.edu", 
                "last_name": "Declan T Barry, Ph.D.", 
                "phone": "203-285-2708"
            }, 
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06519"
                }, 
                "name": "MRU, APT Foundation, Inc"
            }, 
            "investigator": {
                "last_name": "Christopher J Cutter, Ph.D.", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Testosterone Replacement for Male Opioid Agonist Maintained Patients", 
        "overall_contact": {
            "email": "declan.barry@yale.edu", 
            "last_name": "Declan T Barry, Ph.D.", 
            "phone": "203-285-2708"
        }, 
        "overall_contact_backup": {
            "email": "richard.schottenfeld@yale.edu", 
            "last_name": "Richard Schottenfeld, M.D.", 
            "phone": "203-974-7349"
        }, 
        "overall_official": [
            {
                "affiliation": "Yale University", 
                "last_name": "Christopher J Cutter, Ph.D.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Yale University", 
                "last_name": "Declan T Barry, Ph.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Reduced illicit substance use will be assessed by urine toxicology and self-report.", 
                "measure": "Reduced illicit substance use", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Pain reduction will be assessed by self-report ratings.", 
                "measure": "Pain reduction", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Decreased sexual dysfunction will be assessed on self-report measures.", 
                "measure": "Decreased sexual dysfunction", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01873989"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Yale University", 
            "investigator_full_name": "Declan Barry", 
            "investigator_title": "Assistant Professor of Psychiatry", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Yale University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yale University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}